Macrophages Drive Neovascular Remodeling in Neovascular Age-Related Macular Degeneration

About the Research Project
Program
Award Type
Standard
Award Amount
$120,000
Active Dates
July 01, 2014 - June 30, 2016
Grant ID
M2014099
Co-Principal Investigator(s)
Scott Cousins, MD, Duke University School of Medicine
Goals
Our research is trying to understand what causes the severe form of wet macular degeneration, a common disease that damages the back of the eye (retina) and is one of the leading causes of blindness in the United States. Macrophages are cells in the body that fight off infection, but in some cases, they can cause damage to tissues in the body. We are trying to determine how macrophages make neovascular, or “wet” macular degeneration, worse and harder to treat with available medicines. If we can understand how macrophages make this disease worse, our hope is that we can develop new medicines to treat patients with the disease who otherwise might continue to lose vision.
Summary
We are trying to understand what causes the severe form of wet age-related macular degeneration (AMD), one of the leading causes of blindness in the United States. This work is significant because patients with a severe form of the disease do not respond to available medications. Macrophages are cells in the body that fight off infection, but that, in some cases, can cause damage to tissues in the body. We are working to identify the subsets of macrophages in the body that drive the severe form of wet macular degeneration, which is also known as neovascular remodeling. Patients with neovascular remodeling have a disease that is characterized by more complex blood vessel structures and scar tissue formation. Using models of new vessel formation, we will identify which subsets drive neovascular remodeling, and what molecule signals they produce to promote disease. We can use this information to develop new medications that target these macrophage subsets and molecular signals, with the overall goal of improving vision and preventing blindness among patients with severe wet AMD.
Related Grants
Macular Degeneration Research
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Krishna Singh, PhD
Current Organization
Johns Hopkins University School of Medicine
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Krishna Singh, PhD
Current Organization
Johns Hopkins University School of Medicine
Macular Degeneration Research
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Shintaro Shirahama, MD, PhD
Current Organization
Schepens Eye Research Institute of Massachusetts Eye and Ear
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Shintaro Shirahama, MD, PhD
Current Organization
Schepens Eye Research Institute of Massachusetts Eye and Ear
Macular Degeneration Research
Regeneration of Cone Photoreceptors in the Human Retina
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Juliette Wohlschlegel, PhD
Current Organization
University of Washington
Regeneration of Cone Photoreceptors in the Human Retina
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Juliette Wohlschlegel, PhD
Current Organization
University of Washington